Manjari Lal, PhD

Dr. Lal has been working at PATH for the last 14 years with a focus on technologies for the development of thermostable formulations of vaccines (co-adjuvanted), proteins, and small molecule drugs for use in low and medium-income countries (LMICs). Specifically, Dr. Lal leads and oversees the work on novel technology evaluation, process optimization, qualification of sensitive analytical assays, suitable packaging presentations, product stability evaluation following ICH guidelines, and preclinical studies involving novel administration routes for stable vaccine or pharmaceutical drug products.